Since the RV144 vaccine combination showed efficacy in a Phase III trial, it provides an opportunity to generate hypotheses about the immune responses necessary for protection against HIV-1 infection, and these results could help devise vaccine candidates with higher efficacy. Here we describe how researchers can determine the correlates of immune protection for an HIV/AIDS vaccine, particularly in the context of the RV144 trial, and we discuss the terminology used to describe correlates and surrogates.
Get full access to this article
View all access options for this article.
References
1.
PrenticeRL. Surrogate endpoints in clinical trials: Definition and operational criteria. Stat Med, 1989; 8,4:431–440.
2.
FrangakisCE, RubinDB. Principal stratification in causal inference. Biometrics, 2002; 58,1:21–29.
3.
QinL, GilbertPBet al.A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis, 2007; 196,9:1304–1312.
BorganO.et al.Exposure stratified case-cohort designs. Lifetime Data Anal, 2000; 6,1:39–58.
6.
GilbertP.B.et al.Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis, 2005; 191,5:666–677.
7.
ForthalD.N.et al.Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol, 2007; 178,10:6596–6603.
8.
FollmannD. Augmented designs to assess immune response in vaccine trials. Biometrics, 2006; 62,4:1161–1169.
9.
GilbertPB, QinLet al.Evaluating a surrogate endpoint at three levels, with application to vaccine development. Stat Med, 2008; 27,23:4758–4778.
10.
QinL, GilbertPBet al.Assessing surrogate endpoints in vaccine trials with case-cohort sampling and the cox model. Ann Appl Stat, 2008; 2,1:386–407.
11.
GilbertPB, HudgensMG. Evaluating candidate principal surrogate endpoints. Biometrics, 2008; 64,4:1146–1154.
12.
GilbertPB, QinLet al.Response to Andrew Dunning's comment on ‘evaluating a surrogate endpoint at three levels, with application to vaccine development.’Stat Med, 2009; 28,4:716–719.
13.
WolfsonJ, GilbertP. Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials. Biometrics, 2020; 66,4:1153–1161.
